What's new? Log in Free sign up

Kura Oncology (KURA)

Company Profile

Company profile

Ticker

KURA

Exchange

Website

kuraoncology.com

CEO

Dr. Troy Edward Wilson J.D., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

ZETA ACQUISITION CORP III

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

KURA stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$28.67

Low target

$10.00

High target

$40.00

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Registration of securities for employees

28 Feb 25

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers

Entry into a Material Definitive Agreement

Quarterly report

7 Nov 24

Kura Oncology Reports Third Quarter 2024

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

ARMISTICE CAPITAL, LLC

Paradigm Biocapital Advisors LP

SUVRETTA CAPITAL MANAGEMENT, LLC

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND L P

THOMAS JAMES DOYLE

Teresa Brophy Bair

Financial summary

Financial statements Chart KURA financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	224.46 mm	224.46 mm	224.46 mm	224.46 mm	224.46 mm	224.46 mm
Cash burn (monthly)	(no burn)	(no burn)	25.45 mm	20.59 mm	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	52.92 mm	42.82 mm	n/a	n/a
Cash remaining	n/a	n/a	171.54 mm	181.64 mm	n/a	n/a
Runway (months of cash)	n/a	n/a	6.7	8.8	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

KURA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	187	180	+3.9%
Opened positions	50	24	+108.3%
Closed positions	43	18	+138.9%
Increased positions	70	60	+16.7%
Reduced positions	36	55	-34.5%

13F shares	Current	Prev Q	Change
Total value	670.57 bn	1.59 tn	-57.8%
Total shares	82.33 mm	91.83 mm	-10.3%
Total puts	106.20 k	34.00 k	+212.4%
Total calls	101.20 k	40.60 k	+149.3%
Total put/call ratio	1.0	0.8	+25.3%

Largest owners	Shares	Value	Change
BlackRock	7.93 mm	$69.11 bn	+10.9%
Armistice Capital	5.80 mm	$50.52 bn	+118.2%
Suvretta Capital Management	5.08 mm	$44.22 bn	-33.7%
Vanguard	4.82 mm	$41.97 bn	+14.6%
Ra Capital Management	4.45 mm	$38.77 bn	NEW
EcoR1 Capital	3.56 mm	$30.98 bn	-38.7%
Biotechnology Value Fund L P	3.41 mm	$27.37 mm	-19.1%
STT State Street	3.35 mm	$29.14 bn	+25.4%
MS Morgan Stanley	3.27 mm	$28.52 bn	+171.3%
BVF	2.57 mm	$22.36 bn	-23.9%

Largest transactions	Shares	Bought/sold	Change
Deerfield Management	0.00	-5.41 mm	EXIT
Flynn James E	0.00	-5.31 mm	EXIT
Ra Capital Management	4.45 mm	+4.45 mm	NEW
Paradigm Biocapital Advisors	0.00	-4.33 mm	EXIT
Armistice Capital	5.80 mm	+3.14 mm	+118.2%
Suvretta Capital Management	5.08 mm	-2.58 mm	-33.7%
Holocene Advisors	226.90 k	-2.46 mm	-91.6%
EcoR1 Capital	3.56 mm	-2.25 mm	-38.7%
MS Morgan Stanley	3.27 mm	+2.07 mm	+171.3%
Deep Track Capital	0.00	-1.96 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KURA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Jan 25	Francis Burrows	Common Stock	Sell	Dispose S	No	No	7.8719	1,320	10.39 k	20,705
28 Jan 25	Francis Burrows	Common Stock	Sell	Dispose S	No	No	7.8719	846	6.66 k	22,025
28 Jan 25	Brian T. Powl	Common Stock	Sell	Dispose S	No	No	7.8719	1,583	12.46 k	59,667
28 Jan 25	Mollie Leoni	Common Stock	Sell	Dispose S	No	No	7.8719	541	4.26 k	88,253
28 Jan 25	Mollie Leoni	Common Stock	Sell	Dispose S	No	No	7.8719	816	6.42 k	88,794
28 Jan 25	Mollie Leoni	Common Stock	Sell	Dispose S	No	No	7.8719	1,353	10.65 k	89,610
28 Jan 25	Mollie Leoni	Common Stock	Sell	Dispose S	No	No	7.8719	2,253	17.74 k	90,963
28 Jan 25	Teresa Brophy Bair	Common Stock	Sell	Dispose S	No	No	7.8719	4,844	38.13 k	107,948
28 Jan 25	Teresa Brophy Bair	Common Stock	Sell	Dispose S	No	No	7.8719	2,437	19.18 k	112,792
28 Jan 25	Kathleen Ford	Common Stock	Sell	Dispose S	No	No	7.8719	1,817	14.30 k	21,367

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $40 price target.

Kura Oncology Q4 GAAP EPS $(0.22) Beats $(0.65) Estimate, Sales $53.88M Beat $8.50M Estimate

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.65) by 66.15 percent. This is a 60 percent increase over losses of $(0.55) per share from the

Earnings Scheduled For February 26, 2025

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

Press releases

From Benzinga Pro

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.